Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical study

Abstract Immunotherapeutic drugs are promising medicines for cancer treatment. A potential candidate for immunotherapy is interleukin-12 (IL-12), a cytokine well known for its ability to mediate antitumor activity. We developed a plasmid encoding human IL-12 devoid of an antibiotic resistance gene (...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bostjan Markelc, Tanja Jesenko, Simona Kranjc Brezar, Masa Omerzel, Ursa Lampreht Tratar, Andrej Rencelj, Urska Matkovic, Katarina Znidar, Spela Kos, Kristina Levpuscek, Ziva Pisljar, Ursa Kesar, Tilen Komel, Tim Bozic, Aneja Tuljak, Rosana Hudej, Matjaz Peterka, Urska Kamensek, Andrej Cör, Gorana Gasljevic, Alenka Nemec Svete, Natasa Tozon, Gregor Sersa, Maja Cemazar
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-09-01
Col·lecció:	Scientific Reports
Matèries:	Plasmid DNA Interleukin 12 Electroporation Gene electrotransfer CT26 colorectal carcinoma
Accés en línia:	https://doi.org/10.1038/s41598-024-73314-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!